Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs

Author:

Shimizu Yuki,Sasaki Takamitsu,Takeshita Jun-ichiORCID,Watanabe Michiko,Shizu Ryota,Hosaka Takuomi,Yoshinari KouichiORCID

Abstract

Drug-induced liver injury (DILI) is one of major causes of discontinuing drug development and withdrawing drugs from the market. In this study, we investigated chemical properties associated with DILI using in silico methods, to identify a physicochemical property useful for DILI screening at the early stages of drug development. Total of 652 drugs, including 432 DILI-positive drugs (DILI drugs) and 220 DILI-negative drugs (no-DILI drugs) were selected from Liver Toxicity Knowledge Base of US Food and Drug Administration. Decision tree models were constructed using 2,473 descriptors as explanatory variables. In the final model, the descriptor AMW, representing average molecular weight, was found to be at the first node and showed the highest importance value. With AMW alone, 276 DILI drugs (64%) and 156 no-DILI drugs (71%) were correctly classified. Discrimination with AMW was then performed using therapeutic category information. The performance of discrimination depended on the category and significantly high performance (>0.8 balanced accuracy) was obtained in some categories. Taken together, the present results suggest AMW as a novel descriptor useful for detecting drugs with DILI risk. The information presented may be valuable for the safety assessment of drug candidates at the early stage of drug development.

Funder

Ministry of Education, Culture, Sports, Sciences and Technology of Japan

The Mochida Memorial Foundation for Medical and Pharmaceutical Research

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference34 articles.

1. US Food and Drug Administration. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009.

2. Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges;RA Wilke;Nat Rev Drug Discov,2007

3. Lessons learned from the fate of AstraZeneca’s drug pipeline: A five-dimensional framework;D Cook;Nat Rev Drug Discov,2014

4. Drug induced liver injury: an update;M Garcia-Cortes;Arch Toxicol,2020

5. Idiosyncratic drug hepatotoxicity;N Kaplowitz;Nat Rev Drug Discov,2005

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3